Bibliographic Details
| Title: |
Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers. |
| Authors: |
Davis J; Research Clinical Pharmacology, Pfizer Inc, Sandwich, Kent, United Kingdom. john.davis@pfizer.com, Hackman F, Ndongo MN, Choo H, Lewis D, Tawadrous M, Goodrich J, Langdon G |
| Source: |
Clinical therapeutics [Clin Ther] 2010 Oct; Vol. 32 (11), pp. 1889-95. |
| Publication Type: |
Clinical Trial, Phase I; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: |
Publisher: Excerpta Medica Country of Publication: United States NLM ID: 7706726 Publication Model: Print Cited Medium: Internet ISSN: 1879-114X (Electronic) Linking ISSN: 01492918 NLM ISO Abbreviation: Clin Ther Subsets: MEDLINE |
| Database: |
MEDLINE Ultimate |
